Business PR Newswire Innovent’s Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 rvrisingnetwork October 27, 2025 The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight…
